Mostrando 10 resultados de: 44
Filtros aplicados
Publisher
Pharmacogenomics(7)
European Journal of Clinical Pharmacology(6)
Drug Metabolism and Drug Interactions(5)
Pharmacogenomics Journal(4)
Current Drug Targets(2)
Área temáticas
Farmacología y terapéutica(40)
Enfermedades(21)
Bioquímica(13)
Medicina y salud(7)
Fisiología humana(6)
Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs
ReviewAbstract: CYP2D6 is described as the most relevant enzyme in the metabolism of many antipsychotic drugs. Its cPalabras claves:Antipsychotic drugs, CYP2D6, pharmacogenetics, PharmacogenomicsAutores:Adrián LLerena, Berecz R., Cáceres M.C., Dorado P., Penãs-Lledó E.M.Fuentes:scopusAnalysis of diclofenac and its metabolites by high-performance liquid chromatography: Relevance of CYP2C9 genotypes in diclofenac urinary metabolic ratios
ArticleAbstract: In humans, diclofenac is metabolised to 4′-hydroxy (OH), 3′-OH and 5-OH metabolites. The polymorphicPalabras claves:CYP2C9 genotypes, Diclofenac, HydroxydiclofenacAutores:Adrián LLerena, Berecz R., Cáceres M.C., Dorado P.Fuentes:scopusAntipsychotic drugs and QTc prolongation: The potential role of CYP2D6 genetic polymorphism
ReviewAbstract: Although the most common, and usually serious, side effects of first-generation (or typical) antipsyPalabras claves:Antipsychotic drugs, Cardiac side effects, CYP2D6, drug metabolism, QT interval lengthening, Torsades de pointes-type arrhythmiaAutores:Adrián LLerena, Berecz R., Dorado P., Penãs-Lledó E.M.Fuentes:scopusCYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers
ArticleAbstract: Objective: This study analyzed the frequency of CYP2C9 variant alleles and evaluated the impact of CPalabras claves:CYP2C9, Diclofenac, GenotypingAutores:Adrián LLerena, Berecz R., Dahl M.L., Dorado P., Norberto M., Yasar U.Fuentes:scopusCYP2D6 ethnic variability in hispanics
Book PartAbstract: Genetic polymorphism in the CYP2D6 gene results in a wide variability in CYP2D6 enzymatic activity,Palabras claves:Autores:Adrián LLerena, Dorado P., Naranjo M.E.G., Penãs-Lledó E.M.Fuentes:scopusCYP2D6 genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population
ArticleAbstract: Purpose: Cytochrome P450 2D6 (CYP2D6) genotypes and the dextromethorphan/dextrorphan (DXM/DXT) metabPalabras claves:CYP2D6, dextromethorphan, ECUADOR, pharmacogeneticsAutores:Adrián LLerena, Dorado P., Enrique Terán, Francisco J.López Hernández, Machín E., Natalia HerasFuentes:scopusCYP2D6 polymorphism: Implications for antipsychotic drug response, schizophrenia and personality traits
ReviewAbstract: The CYP2D6 gene is highly polymorphic, causing absent (poor metabolizers), decreased, normal or incrPalabras claves:Adverse side effects, antipsychotics, CYP2D6, personality, pharmacogenetics, Pharmacogenomics, QTc, Schizophrenia, vulnerabilityAutores:Adrián LLerena, Dorado P., Penãs-Lledó E.M.Fuentes:scopusCYP2D6 poor metabolizer status might be associated with better response to risperidone treatment
ArticleAbstract: The variability in the antipsychotic response is, to some extent, genetically determined. Several stPalabras claves:CYP2D6, EFFECTIVENESS, MDR1, pharmacogenetics, Risperidone, SchizophreniaAutores:Abad-Santos F., Adrián LLerena, Almoguera B., Ayuso C., Baca-García E., Dal-Ré R., Dorado P., Fernandez-Piqueras J., Lopez-Castroman J., Riveiro-Alvarez R., Vaquero-Lorenzo C.Fuentes:scopusEating disorder symptoms and CYP2D6 variation in cuban healthy females: A report from the Ibero-American network of pharmacogenetics
ArticleAbstract: CYP2D6 is involved in the metabolism of antidepressants drugs and of the endogenous neurotransmitterPalabras claves:Cuban population, CYP2D6, Eating disorder symptoms, Global pharmacogenetics, Healthy females, Public health pharmacogenetics, Ultrarapid metabolizersAutores:Adrián LLerena, Alvárez M., Calzadilla L.R., Dorado P., González I., Naranjo M.E.G., Penãs-Lledó E.M., Pérez B.Fuentes:scopusEffect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions
ArticleAbstract: Objectives: CYP2D6 drug-metabolising enzyme has been shown to be involved in fluoxetine metabolism iPalabras claves:CYP2C9, CYP2D6, Selective serotonin reuptake inhibitorsAutores:Adrián LLerena, Berecz R., Dorado P., González A.P., Penãs-Lledó E.M.Fuentes:scopus